C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
LifeArc and C4X Discovery join forces to develop small molecule drug candidates active against a high value, novel oncology and inflammation target
27 November 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a discovery partnership with LifeArc®, one of the UK’s leading medical research charities. C4XD and LifeArc will join forces to progress medicinal chemistry efforts on a novel, commercially attractive programme with applicability across oncology and inflammation indications. The undisclosed target originated from LifeArc’s extensive partnerships in early-stage academic research.
The partnership will combine leading drug discovery expertise from both organisations, including application of C4XD’s unique and proprietary ligand-focussed conformational analysis platform, Conformetrix, to LifeArc’s extensive background and experience in the programme. The aim is to develop oral, potent and selective small molecule drug candidates against the undisclosed target suitable for pre-clinical out-licensing to a clinical development partner and, ultimately, to deliver a novel treatment in an area of high unmet clinical need.
This discovery partnership adds a high value programme to C4XD’s portfolio. Furthermore, it demonstrates continued progress against its stated strategy of utilising its cutting-edge drug discovery engine, and establishing productive partnerships, to develop novel small molecules against targets with high partnering interest.
Terms of the agreement are undisclosed.
Dr Clive Dix, CEO of C4X Discovery, said: “LifeArc is a highly-respected medical charity with access to world-leading academic research for conditions where there is a clear need for new treatments coupled with deep experience in drug discovery. This partnership not only demonstrates the potential of our Conformetrix platform, it also highlights our strategic approach of accelerating towards a diversified portfolio of pre-clinical assets for out-licensing. We are delighted to be working with the LifeArc team and look forward to a successful outcome and continuing to build on our strategic relationship.”
Dr Justin Bryans, LifeArc’s Executive Director, Drug Discovery, added: “LifeArc is delighted to partner with C4XD. Our new partner’s expertise in the rapid design and analysis of novel small molecule therapeutics complements LifeArc’s drug discovery expertise. C4XD’s focus on diseases with high unmet medical need is entirely in line with our objective of ensuring that innovative life sciences technologies progress along their development pathway towards the patients who so desperately need them.”
This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.
C4X Discovery Holdings plc
Mo Noonan, Communications+44 (0)7876 444 977
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700
C4X Discovery (C4XD) aims to create the world’s most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company’s business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD’s commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
For additional information please go to:www.c4xdiscovery.com
LifeArc is a medical research charity with over 25 years’ experience in helping scientists and organisations turn their research into effective diagnostics and treatments. LifeArc collaborates with a wide range of life science charities and other partners. In addition to portfolio review, IP protection, technology transfer and licensing LifeArc also offers its partners expertise in; early stage research funding, diagnostics development, drug discovery, scientific scouting, campaigning, drug discovery pipeline, in vitro diagnostics and antibody engineering.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.